Utilized for attention deficit hyperactivity disorder to manage focus levels and support behavioral regulation.
Mechanism of Action
Atomoxetine selectively inhibits the presynaptic norepinephrine transporter. This increases the synaptic concentration of norepinephrine in the prefrontal cortex, which is associated with improved attention and impulse control.
Route of Administration
Oral
Onset Time
1–4 weeks
Duration
24 hours
Contraindications
Narrow-angle glaucoma, Pheochromocytoma, Concurrent use of MAO inhibitors, Hypersensitivity to atomoxetine
Severe Adverse Events
Suicidal ideation, Hepatotoxicity, Priapism — requires immediate medical attention
Common Side Effects
Nausea, Decreased appetite, Dry mouth
Uncommon Side Effects
Somnolence, Insomnia, Abdominal pain
Drug Interactions
Alcohol, MAO Inhibitors, Fluoxetine, Paroxetine, Albuterol
Pregnancy Safety Warnings
FDA Category C: Use only if potential benefit outweighs risk. Breastfeeding: Use with caution.
Age Restrictions
Safety and efficacy established in pediatric patients six years and older.
Information related to Atomoxetine is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
